ANITA/ ENGOT-Ov41/ GEICO 69-O

A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months 

Contact Person
Status
Closed to Recruitment
Disease Site
Ovarian
Lead Cooperative Group
Participating Groups
GINECO
AGO
BGOG
MaNGO
ISGO
GCIG Number